NIVABUPA79.47

Niva Bupa Health Insurance Company Ltd.

· Banking & Finance
AnnualQuarterly₹ CrorePeersSTARHEALTHICICIGINIACLSAMMAANCAPSBFCJ&KBANKIEXHOMEFIRST
View
In ₹ Crore except Per Share
12 Months Ending
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Other Income-56.51.617.96.6-24.8
Revenue Detail — as filed
+ Operating Income1,564.71,308.41,538.11,549.52,077.7
+ Income from Investments (net)93.886.898.189.3130.5
Expense Detail — as filed
+ Employee Remuneration & Welfare142.3166.2165.5188.9154.7
+ Commission (net)295.5259.8279.8317.6369.5
+ Commission & Brokerage (net)295.5259.8279.8317.6369.5
+ Non-operating Expense-49.710.527.220.2-21.8
+ Non-operating Provision — Doubtful Debts-1.32.02.45.3-5.2
Profit Build-up — Alternate / Pre-Ind-AS Tags
Profit before Extraordinary Items206.1-91.4-35.3-87.6341.2
Profit / (Loss) before Tax — alt tag206.1-91.4-35.3-87.6341.2
+ Provision for Tax0.00.00.00.0-4.0
Profit / (Loss) after Tax206.1-91.4-35.3-87.6345.1
Profit Carried to Balance Sheet-718.5-809.9-845.2-932.8-587.7
Per Share — as-filed variants
Basic & Diluted EPS before Extraordinary (not annualised)1.13-0.50-0.19-0.471.87
Basic & Diluted EPS after Extraordinary (not annualised)1.13-0.50-0.19-0.471.87
Appropriations & Transfers
+ Transfer to Profit & Loss Account94.9-145.2-62.0-135.5282.5
Reserves & Surplus excl. Revaluation Reserve1,231.31,142.61,110.01,024.21,371.5
Insurance — Revenue Account (Policyholders')
Premium Earned1,527.41,220.01,422.11,453.61,972.0
+ Gross Premiums Written2,078.71,631.91,843.12,231.32,879.7
+ Net Premium Written1,672.11,287.91,450.11,766.72,301.7
+ Operating Expenses — Insurance Business312.7243.9307.7316.6306.4
+ Non-operating Expenses — Non-insurance-48.48.424.714.9-16.6
+ Claims Paid824.6849.6960.8946.41,052.3
+ Incurred Claims861.6949.91,012.61,050.91,119.2
+ Change in Outstanding Claims37.0100.451.7104.566.9
Insurance — Shareholders' Account
+ Income — Shareholders' Account156.4-81.0-8.1-67.5319.4
+ Shareholders' Investment Income49.664.253.968.136.1
+ Transfer from Policyholders' Fund94.9-145.2-62.0-135.5282.5
With Unrealised Gains0.00.00.00.0-0.0
Without Unrealised Gains0.00.00.00.00.0
Insurance — Fund NPAs
+ Gross NPAs — Policyholders' Fund54.350.050.050.050.0
Insurance — IRDAI Ratios (as filed, not percentages)
Solvency Ratio3.032.862.852.492.49
Combined Ratio0.931.171.121.080.86
Incurred Claim Ratio0.560.780.710.720.57
Net Retention Ratio0.800.790.790.790.80
Expenses of Management Ratio0.360.380.390.330.28
Regulatory Disclosures — filed alongside, not part of the P&L
Investor Complaints — During the Period-4.00-1.000.000.000.00
Investor Complaints — Received14.000.000.000.000.00
Investor Complaints — Disposed18.001.000.000.000.00
Related-party Transactions — During the Period7.4
Other Filed Concepts — mapped but not yet placed in the schedule
Operating Expenses1,469.81,453.61,600.11,685.11,795.1
Other Operating Expenses170.477.7142.2127.7151.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q4 FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.